摘要 目的：探讨吉非替尼(商品名易瑞沙)治疗非小细胞肺癌的疗效和毒副反应。方法：回顾性分析2005年至2007年我院49例单药吉非替尼250mg治疗复治的非小细胞肺癌患者至少4周，并获得随访，评价总生存时间，疾病控制率，无进展生存期，药物毒副反应。结果：总生存时间9月，疾病控制率66%,无进展生存期6.6月，未出现III度Ⅳ度药物毒性反应。结论：吉非替尼可以显著改善非小细胞肺癌临床症状和生活质量，且耐受性好，是一种适合我国人民的靶向治疗药物。

    关键词 吉非替尼；非小细胞肺癌

    Abstract Objectiv：To ascertain clinical experience and toxic reactions of treating NSCLC by Gefitinib. Methods：Clinic data of 49 cases NSCLC were collected analysed treated by Gefitinib from 2005-2007.Evaluation were made about curative effect ,quality of life ,mediun survive time,time to progression,toxic action.Result：Forty-nine pations were follow up. Mean survive time of all patiaons was 9 months.,total clinic control rate was 66%. Time to prograss was 6 months. Ⅲ-Ⅳ grades of toxic reaction were not founded.Conclusion：Gefitinib may obviously improve the clinical symptom and QOL of NSCLC patients.It is a kind of molecule-tagets medicient suited with chineses.

    Keywords Gefitinib；Non-small cell lung cancer

    改善生活质量 ......